This CME activity will feature four HIV experts reviewing and discussing the most important studies presented on antiretroviral therapy at CROI. This review and discussion will provide unique insight into how knowledgeable experts review the key posters and presentations at CROI and an in-depth understanding of the scientific quality and clinical relevance of the posters and presentations reviewed.
This activity will enable all participating clinicians and health care providers caring for HIV-infected patients to become aware of and understand the data presented at this important conference and appropriately utilize those data to improve patient care.
This activity is intended for physicians, physician assistants, advanced practice nurses, and other health care professionals involved in the treatment and management of patients with HIV infection.
After completing this activity, participants should be able to:
Review clinically relevant poster presentations made at the 19th CROI;
Explain to colleagues the clinical trials and data presented in the most important poster presentations at the 19th CROI;
Discuss the scientific integrity and clinical relevance of the most important poster presentations at the 19th CROI;
Use the information and data presented in the most important poster presentations at the 19th CROI to improve patient care.
Release Date:
Expiration Date:
Estimated time to complete each Poster/Presentation: 15-30 minutes
Media: Internet
Trevor Hawkins, MD
Associate Professor, University of New Mexico
Medical Director, Southwest CARE Center
Santa Fe, New Mexico
Paul Sax, MD
Clinical Director, Brigham and Women's Division
of Infectious Diseases and HIV Program
Associate Professor of Medicine, Harvard Medical School
Boston, Massachusetts
Renslow Sherer, MD
Professor of Medicine
Section of Infectious Diseases and Global Health
University of Chicago,
Chicago, Illinois
Andrew Zolopa, MD
Professor of Medicine
Division of Infectious Diseases
Stanford University School of Medicine
Palo Alto, California
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of the Postgraduate Institute for Medicine and ViralEd, Inc.. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
There will be 10 posters and presentations, each of which will offer 0.25 credit hours, for a maximum of 2.50 possible credit hours.
The Postgraduate Institute for Medicine assesses conflict of interest with its instructors, planners, managers and other individuals who are in a position to control the content of CME activities. All relevant conflicts of interest that are identified are thoroughly vetted by PIM for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. The Postgraduate Institute for Medicine is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of a commercial interest.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Dr. Trevor Hawkins:
Dr. Paul Sax:
Dr. Renslow Sherer:
Dr. Andrew Zolopa:
The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:
The following PIM staff serve as clinical content reviewers and/or participate in planning CME/CE activities in a manner that may affect content:, Laura Excell, ND, NP, MS, MA, LPC, NCC; Trace Hutchison, PharmD; Samantha Mattiucci, PharmD, CCMEP; Jan Shultz, RN, MSN, CCMEP and Patricia Staples, MSN, NP-C, CCRN hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interests related to the content of this CME/CE activity of any amount during the past 12 months.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The Postgraduate Institute for Medicine, ViralEd, Inc. and Merck & Co. do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the Postgraduate Institute for Medicine, ViralEd, Inc. and Merck & Co. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
 |
Nationally Representative Estimates of the Number of HIV+ Adults Who Received Medical Care, Were Prescribed ART, and Achieved Viral Suppression-Medical Monitoring Project, 2009 to 2012: US | |
|
|
Administration of Vorinostat Disrupts HIV-1 Latency in Patients on ART |
|
 |
The FEM-PrEP Trial of Emtricitiabine/Tenofovir Disoproxil Fumarate among African Women |
|
 |
Asymptomatic HIV-associated Neurocognitive Disorder (ANI) Increases Risk for Future Symptomatic Decline: A CHARTER Longitudinal Study |
|
 |
Week 48 Results of an Ongoing Phase 3 Study Comparing EVG/COBI/TDF/FTC with ATVr+TDF/FTC in Treatment-naive HIV-1+ Subjects Showing Efficacy, Safety and Pharmakokinetics
EVG/COBI/TDF/FTC Has Non-inferior Efficacy and Favorable Safety Compared to EFV/TDF/FTC in Treatment-naive HIV-1+ Subjects |
|
 |
Telaprevir in Combination with Pegylated Interferon 2a + Ribavirin in HCV/HIV co-infected Patients: A 24-Week Treatment Interim Analysis Boceprevir+Pegylated Interferon+Ribavirin for the Treatment of HCV/HIV co-infected Patients: End of Treatment (Week 48) Interim Results |
|
 |
GS‐7977 + Ribavirin in HCV Genotype 1 Null Responders: |
|
 |
Changes in Cardiovascular Biomarkers in Subjects Switching from Protease Inhibitor/ritonavir to Raltegravir: The SPIRAL Study | |
 |
GS-7340 25 mg and 40 mg Demonstrate Superior Efficacy to TDF/FTC 300 mg in a 10-day monotherapy Study of HIV-1+ Patients Dolutegravir in Combination Therapy Exhibits Rapid and Sustained Antiviral Response in ARV-naive Adults: 96-week Results from SPRING-1 (ING112276) |
|
 |
Zostavax® is Generally Safe and Immunogenic in HIV Infected Adults with CD4 Counts ≥200 Cells/μL Virologically Suppressed on ART: Results of a Phase 2, Randomized, Placebo‐Controlled Trial |
|
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Supported by an educational grant from Merck & Co., Inc.
This coverage is not sanctioned by the conference organizers and is not an official part of the conference proceedings
